CD274 and neoplasm: RPPA profiling revealed a significant (false discovery rate (FDR) < 0.05) upregulation of CD274 (PD-L1) in the 344SQ KP tumors when tumor-bearing mice were treated with AZD6244 (Fig. 1a).